The partnership will address the backlog of BMT patients, aiming to provide timely access to critical procedures.

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.